News Archives

News Archives

Avivagen Inc. Announces Stock Option Grants

Ottawa, ON /Business Wire/ March 6, 2020/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that its Board of Directors has approved the issuance of 555,000 stock options, including 465,000 options granted to officers, directors and investor relations personnel of the Corporation. The options, which shall be vested over an eight-quarter period, are exercisable …Read More

Avivagen to be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Avivagen, a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, thereby supporting general health and performance, is pleased to announce that it will be featured on an upcoming BioPub webcast hosted by Dr. KSS on Friday March 6th, 2020 at noon EST. …Read More

Avivagen Inc. Announces Results for the First Quarter Ending January 31, 2020

Ottawa, ON /Business Wire/ March 4, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™  technology, announces its unaudited financial results for the first quarter of 2020. For the three-month period ended January 31, 2020, the Corporation reported revenues of $247,805, a decrease …Read More

Avivagen Announces Positive Results from New Zealand OxC-betaTM Livestock Dairy Trial for Use Against Sub-Clinical Mastitis

Ottawa, ON / Business Wire / February 24, 2020 / – Avivagen Inc.  (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce positive and statistically significant …Read More

Avivagen Finalizes Distribution Agreement with INPHILCO in the Philippines

Deal creates new sales channel and revenue opportunities for OxC-betaTM Livestock with commercial farms and large integrated feed producers Ottawa, ON / Business Wire / February 18, 2020 / – Avivagen Inc.  (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune …Read More

Avivagen Announces CEO Update to Shareholders

Ottawa, ON / Business Wire / January 29, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB: VIVXF) (“Avivagen”) announces its CEO update to shareholders. To our Shareholders: The past twelve months have been a period of exceptional accomplishment and achievement for Avivagen. As a Company, we have taken tremendous strides in the development and commercialization of …Read More